Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 3/20 | 0.50 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.35 |
| ▸ | GLA | P06280 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | GLB1 | P16278 | 1/20 | 0.35 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19599292 | 0.82 | FUCA1 (0.44) | GBA1FUCA1 | |
| SCHEMBL21251753 | 0.82 | FUCA1 (0.44) | GBA1FUCA1 | |
| SCHEMBL22142085 | 0.82 | FUCA1 (0.44) | GBA1FUCA1 | |
| SCHEMBL14592862 | 0.82 | FUCA1 (0.44) | GBA1FUCA1 | |
| SCHEMBL19777063 | 0.80 | GBA1 (0.38) | GBA1 | |
| SCHEMBL21360190 | 0.80 | GBA1 (0.41) | GBA1FUCA1 | |
| SCHEMBL7272167 | 0.80 | GBA1 (0.37) | GBA1 | |
| SCHEMBL21859511 | 0.80 | GBA1 (0.41) | GBA1 | |
| SCHEMBL21859510 | 0.80 | GBA1 (0.41) | GBA1 | |
| SCHEMBL12348830 | 0.80 | GBA1 (0.64) | GBA1FUCA1GLAGAAGLB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2021-04-06 | — | — | US | disclosed |
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2019-09-05 | — | — | US | disclosed |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | NEWAVE PHARMACEUTICAL INC. (US) | 2019-04-09 | — | — | US | disclosed |
| US-10041101-B2 | Compositions comprising a polypeptide having cellulolytic enhancing activity and a heterocyclic compound and uses thereof | NOVOZYMES, INC. (US) | 2018-08-07 | — | — | US | disclosed |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | NOVOZYMES, INC. (US) | 2018-01-18 | — | — | US | disclosed |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | NEWAVE PHARMACEUTICAL INC. | 2017-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190270742-A1 | FGFR4 INHIBITOR, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF | FGFR4, FGFR2, FGFR1 | GBA1 3063/4885CCR5 4106/4885FUCA1 1136/4885 |
| US-20180019412-A1 | Compositions Comprising A Polypeptide Having Cellulolytic Enhancing Activity And A Quinone Compound And Uses Thereof | PGLS, CEL, PNLIP | GBA1 1848/4885CCR5 3699/4885FUCA1 157/4885 |
| US-20170305918-A1 | DUAL-WARHEAD COVALENT INHIBITORS OF FGFR-4 | FGFR4, FGFR2, FGFR3 | GBA1 2904/4885CCR5 1307/4885FUCA1 3391/4885 |
| US-10968220-B2 | FGFR4 inhibitor, preparation method therefor and pharmaceutical use thereof | FGFR4, FGFR2, FGFR1 | GBA1 3063/4885CCR5 4106/4885FUCA1 1136/4885 |
| US-10253029-B2 | Dual-warhead covalent inhibitors of FGFR-4 | FGFR4, FGFR2, FGFR3 | GBA1 2904/4885CCR5 1307/4885FUCA1 3391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.